Menu Search
Equities

Dicot Pharma AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert
KN0:STU

Dicot Pharma AB

Actions
  • Price (EUR)0.0248
  • Today's Change0.001 / 4.20%
  • Shares traded0.00
  • 1 Year change+15.89%
  • Beta1.6389
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Dicot Pharma AB, formerly known as Dicot AB is Sweden- based drug pharmaceutical company primarily engaged in the drug development industry. The Company scope of activity revolves around developing innovations that enhance sexual health. The company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead candidate is LIB-01 which is in the clinical testing. The Company conducted comprehensive preclinical studies, verifying LIB-01’s effect across multiple studies. The active substance in LIB-01 is a semi-synthetically produced molecule based on a folk medicine use. Dicot Pharma AB goal is to develop a completely new generation of potency drugs.

  • Revenue in SEK (TTM)126.00k
  • Net income in SEK-84.00m
  • Incorporated2015
  • Employees4.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.